At a glance
A triple-receptor agonist studied in weight and metabolic disease research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source cites trials measuring weight, glycemic and other metabolic outcomes. Reported benefits and gastrointestinal adverse events must be interpreted within the trial population and follow-up.[3][4][1]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Retatrutide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 2 source tables
Standard / Gradual Approach (1 mL = ~10.0 mg/mL)
| Phase | Weekly Dose | Units (per injection) (mL) | Vials Needed |
|---|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) | 1 vial per dose |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) | 1 vial per dose |
| Weeks 9–12 | 6 mg (6000 mcg) | 60 units (0.60 mL) | 1 vial per dose |
| Weeks 13+ | 8 mg (8000 mcg) | 80 units (0.80 mL) | 1 vial per dose |
Frequency: Inject once weekly subcutaneously[1][2]. All doses ≤10 mg can be drawn from one reconstituted 10 mg vial with 1.0 mL reconstitution. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites to ensure proper absorption[5].
Advanced / Aggressive Protocol (1 mL = ~10.0 mg/mL)
| Phase | Weekly Dose | Units (per injection) (mL) | Vials Needed |
|---|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) | 1 vial per dose |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) | 1 vial per dose |
| Weeks 9–12 | 8 mg (8000 mcg) | 80 units (0.80 mL) | 1 vial per dose |
| Weeks 13+ | 12 mg (12000 mcg) | 120 units (1.20 mL) | 2 vials per dose** |
Note: The 12 mg dose represents the highest dose tested in Phase 2 trials[3][4], producing maximum weight-loss efficacy (~24% body weight at 48 weeks). **The 12 mg dose requires reconstituting 2 vials (each with 1.0 mL); draw 1.20 mL total from the combined 2.0 mL and split into 2 injections at separate sites. Gradual titration is critical to minimize gastrointestinal side effects[6].
Additional schedule context & duration
Concise summary of the once-weekly regimen.
- Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation[1][7].
- Schedule: Weekly subcutaneous injections for 12–48 weeks (clinical trials ranged 36–48 weeks)[2].
- Dose Range: 2–12 mg weekly with gradual 4-week titration steps[3][4].
- Reconstitution: 1.0 mL per 10 mg vial (~10.0 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) for up to 4 weeks[15].
Suggested weekly titration approach from clinical trials.
- Start: 2 mg weekly for 4 weeks to assess tolerance[6].
- Escalate: Increase by 2–4 mg every 4 weeks as tolerated.
- Target: 6–8 mg weekly (standard); 12 mg weekly (advanced/aggressive).
- Frequency: Once per week (subcutaneous), same day each week.
- Cycle Length: Minimum 24 weeks; trials extended to 48 weeks[3][4].
- Timing: Any consistent day/time; rotate injection sites with each dose.
Preparation
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 4 weeks of reconstitution[15].
Storage Instructions
Proper storage preserves peptide quality and stability.
- Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; stable for up to 24 months[15].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks[15].
- Allow vials to reach room temperature before opening to reduce condensation.
- For extended storage, aliquot reconstituted solution and freeze at −20 °C (−4 °F); thaw only once before use[16].
Injection Technique
Subcutaneous injection guidance from clinical best-practice resources[12][13][14].
- Clean the vial stopper and injection site with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
- For volumes >1.0 mL, split into 2 injections at different sites (e.g., left and right abdomen)[5].
- Rotate sites systematically (abdomen preferred; also thighs, upper arms) to avoid lipohypertrophy[13].
- Wait a few seconds after injecting before withdrawing needle to ensure full dose delivery.
- Dispose of used syringes immediately in an FDA-approved sharps container[13].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on a 12–24 week weekly protocol with gradual titration.
- Peptide Vials (Retatrutide, 10 mg each):
- 12 weeks (Standard to 6 mg): 5 vials
- 24 weeks (Standard to 8 mg): 15 vials
- 12 weeks (Aggressive to 8 mg): 6 vials
- Insulin Syringes (U-100, 1 mL capacity):
- Per week: 1–2 syringes (depending on dose; higher doses require split injections)
- 12 weeks: 12–24 syringes
- 24 weeks: 24–48 syringes
- Bacteriostatic Water (10 mL bottles): Use ~1.0 mL per vial for reconstitution.
- 12 weeks (5 vials): 5 mL → 1 × 10 mL bottle
- 24 weeks (15 vials): 15 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for each injection site.
- Per week: 2–4 swabs (1 per vial + 1–2 per injection site)
- 12 weeks: ~50 swabs → recommend 1 × 100-count box
- 24 weeks: ~100 swabs → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 1 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 12
- 13
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (technique, site rotation, sharps disposal) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 14
Public health resource
NCBI Bookshelf — Administration of medication: subcutaneous injections (aseptic technique, preparation) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 16
Continue exploring
Related topics are not interchangeable compounds or formulations.